Endocrine Abstracts

Prostate cancer (PC) is the second most frequently diagnosed cancer in men worldwide. 10–20% of the PC patients develop castration-resistant prostate cancer (CRPC) that has no curative therapies. There are also no effective prognostic markers to predict emergence of CRPCs. Long noncoding RNAs (lncRNAs) are a recently found group of RNAs that are not translated into proteins. Many of them are found to be differentially expressed in cancer, and shown to have a regulative ro...

Prostate cancer is multifocal in nature, and histological grading is the key clinical prognostic factor. To build non-subjective histological analysis tools, and to model the multifocality of prostate cancer within the organ, we use analysis of histological images to quantitatively describe prostate cancer. Our current effort shows how heterogeneity in prostate tissue due to cancer or spatial location can be quantified with image-derived features. We use high-resolution digita...

Prostate cancer (PC) is the most common malignancy and third most common cause of cancer-related death among men in Europe. Although most PCs grow slowly, 20–25% of the patients believed to have organ-confined disease will experience biochemical recurrence already during 5-years of follow-up. The standard treatment against advanced PC is androgen deprivation (ADT). Unfortunately, androgen deprivation treatment eventually fails leading to the emergence of castration resist...

Epigenetic reprogramming including altered transcription factor binding and altered patterns of chromatin and DNA modifications are now accepted as the hallmark of aggressive cancers. We show that global changes in chromatin structure and chromatin accessibility in prostate tumour tissue can define castrate-resistant prostate cancer and be used to inform the discovery of gene-level classifiers for therapy. In addition, we show that the androgen receptor overexpression alone, w...